Medicare AdvantageDecember 6, 2024
Clinical Criteria updates
Effective January 9, 2025
Summary: On September 20, 2024 and October 2, 2024 the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other members of your practice and office staff.
Please note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised |
January 9, 2025 | *CC-0267 | Ebglyss (lebrikizumab-lbkz) | New |
January 9, 2025 | *CC-0268 | Lymphir (denileukin diftitox-cxdl) | New |
January 9, 2025 | *CC-0269 | Nemluvio (nemolizumab-ilto) | New |
January 9, 2025 | *CC-0270 | Niktimvo (axatilmab-csfr) | New |
January 9, 2025 | *CC-0271 | Tecelra (afamitresgene autoleucel) | New |
January 9, 2025 | *CC-0012 | Brineura (cerliponase alfa) | Revised |
January 9, 2025 | *CC-0250 | Veopoz (pozelimab-bbfg) | Revised |
January 9, 2025 | *CC-0072 | Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised |
January 9, 2025 | *CC-0029 | Dupixent (dupilumab) | Revised |
January 9, 2025 | CC-0201 | Rybrevant (amivantamab-ymjw) | Revised |
January 9, 2025 | CC-0130 | Imfinzi (durvalumab) | Revised |
January 9, 2025 | *CC-0002 | Colony Stimulating Factor Agents | Revised |
January 9, 2025 | CC-0050 | Monoclonal Antibodies to Interleukin-23 | Revised |
January 9, 2025 | *CC-0011 | Ocrevus (ocrelizumab)/Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq) | Revised |
Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
CABC-CR-071473-24-CPN71236
PUBLICATIONS: January 2025 Provider Newsletter
To view this article online:
Visit https://providernews.anthem.com/california/articles/clinical-criteria-updates-23291
Or scan this QR code with your phone